H. Pylori Eradication for Moderate ITP
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03177629 |
Recruitment Status : Unknown
Verified September 2018 by Soo-Mee Bang, Seoul National University Hospital.
Recruitment status was: Recruiting
First Posted : June 6, 2017
Last Update Posted : September 7, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Immune Thrombocytopenic Purpura Helicobacter Pylori Immune Thrombocytopenia | Drug: treatment : H. pylori eradication | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 54 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | treatment group vs control group Patients in treatment group will be treated with antibiotics for H. pylori eradication at visit 1. Control group has 2 stage. Fot the 1st stage (for 3 months), the patient will be observed without any treatment. And at visit 4, at 2nd stage, they will be treated with the same regimen for H. pylori eradication. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study |
Actual Study Start Date : | May 23, 2017 |
Estimated Primary Completion Date : | June 2020 |
Estimated Study Completion Date : | December 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment arm: H. pylori eradication
treatment arm: H. pylori eradication at visit 1(0 month)
|
Drug: treatment : H. pylori eradication
treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4. Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO |
No Intervention: Control arm -1st stage
At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
|
|
Active Comparator: Control arm - 2nd stage
Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
|
Drug: treatment : H. pylori eradication
treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4. Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO |
- overall response rate (ORR: complete response + response rate) of platelets [ Time Frame: visit 4 (3 months after randomization) ]
- ORR between treatment group with UBT (-) and control group with stage 1
- International working group criteria for ITP treatment response will be used for ORR definition
- ORR between treatment group and control group with stage 1 [ Time Frame: visit 4 (3 months after randomization) ]all patients in the treatment group (with UBT (+) or UBT (-) patients)
- ORR of control group with stage 2 [ Time Frame: At visit 5 (6 months after randomization) ]patients in the control group with stage 2 with UBT (-)
- ORR after H. pylori eradication in all patients who were treated and UBT (-) [ Time Frame: 3 months after H. pylori eradication ]UBT (-) patients in treatment group and control group with stage 2
- Time to response [ Time Frame: from initiation date of study drugs to the date of R or CR (assessed up to 6 months) ]from initiation date of study drugs to the date of R or CR in treatment group
- Response duration [ Time Frame: from the date of R or CR to the date of loss of R or CR / or till last f/u date, whichever came first (assessed up to 6 months) ]from the date of R or CR to the date of loss of R or CR / or till last f/u date in treatment group
- H. pylori eradication rate [ Time Frame: at vist 4 (3 months after randomization) after drug treatment ]defined by UBT (-)
- drug toxicity and compliance [ Time Frame: At visit 2, 3, 4, 5 (1, 2, 3, 6 months after randomization, respectively) for treatment group, at visit 5 (6 months after randomization) for control group stage 2 ]NCI CTCAE v4.0 for safety measurement, 85% of taking medicine for criteria of compliance
- QoL [ Time Frame: At visit 1(Day 1 of study drug medication) & vist 4 (3 months after randomization) ]within & between group after H. pylori eradication, FACIT-F, FACIT-Th6
- platelet level at randomization [ Time Frame: 3 months after H. pylori eradication ]comparison of platelet level at randomization between treatment responder and non-responder of H. pylori eradication
- ITP duration before randomization [ Time Frame: 3 months after H. pylori eradication ]comparison of ITP duration before randomization between treatment responder and non-responder of H. pylori eradication

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 19 years
- Persistent or chronic ITP patients defined by international working group
- 30 X 10^9/L ≤ platelet level ≤ 80 X 10^9/L
- H. pylori infection should be confirmed by at least one of tests: urea breath test (UBT), CLO, stool H. pylori Ag, H. pylori in gastric tissue (reported by a trained pathologist)
- No history of any ITP treatment for the past 3 months
- No previous history of H. pylori eradication treatment
- Patients who voluntarily participate in this study and with informed consents
Exclusion Criteria:
- patients who have any cause of thrombocytopenia such as HIV, HCV infection, lymphoproliferative disease, malignant neoplasm, liver disease, definite SLE and other autoimmune diseases, drugs, MDS and leukemia
- uncontrolled hypothyroidism or hyperthyroidism
- active bleeding for the past 3 months or history of hemorrhagic gastric ulcer or brain hemorrhage
- active infection
- patients who are taking anticoagulant or aspirin
- patients with penicillin allergy or side effects of macrolide
- patients who are taking mizolastine, terfenadine, cisapride, pimozide, astemizole, ergot alkaloid and its derivatives (ergotamine and dihydroergotamine), bepridil or atazanavir
- patients who have known allergy or severe side effect on study drugs
- pregnant or lactating women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03177629
Contact: Soo-Me Bang, M.D. | 82 31 787 7039 | smbang7@snu.ac.kr | |
Contact: HYO JUNG KIM, M.D. | 82 31 380 3704 | hemonc@hallym.or.kr |
Korea, Republic of | |
Seoul National University Bundang Hospital | Recruiting |
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707 | |
Contact: Soo-Mee Bang, M.D. 82 31 787 7039 smbang7@snu.ac.kr |
Principal Investigator: | Soo-Me Bang, M.D. | Seoul National University Bundang Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Soo-Mee Bang, Professor, Department of Internal Medicine, Seoul National University Hospital |
ClinicalTrials.gov Identifier: | NCT03177629 |
Other Study ID Numbers: |
KSH_ITP1701 |
First Posted: | June 6, 2017 Key Record Dates |
Last Update Posted: | September 7, 2018 |
Last Verified: | September 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Immune Thrombocytopenic Purpura Helicobacter pylori |
Thrombocytopenia Purpura Purpura, Thrombocytopenic, Idiopathic Purpura, Thrombocytopenic Blood Platelet Disorders Hematologic Diseases Blood Coagulation Disorders |
Hemorrhage Pathologic Processes Skin Manifestations Thrombotic Microangiopathies Hemorrhagic Disorders Autoimmune Diseases Immune System Diseases |